SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-030467
Filing Date
2021-06-02
Accepted
2021-06-02 14:43:28
Documents
36
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0321_rasnathera.htm   iXBRL 10-Q 349661
2 CERTIFICATION f10q0321ex31-1_rasnathera.htm EX-31.1 9662
3 CERTIFICATION f10q0321ex32-1_rasnathera.htm EX-32.1 3484
  Complete submission text file 0001213900-21-030467.txt   1864262

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rasp-20210331.xsd EX-101.SCH 19331
5 XBRL CALCULATION FILE rasp-20210331_cal.xml EX-101.CAL 21325
6 XBRL DEFINITION FILE rasp-20210331_def.xml EX-101.DEF 95100
7 XBRL LABEL FILE rasp-20210331_lab.xml EX-101.LAB 189568
8 XBRL PRESENTATION FILE rasp-20210331_pre.xml EX-101.PRE 101186
9 EXTRACTED XBRL INSTANCE DOCUMENT f10q0321_rasnathera_htm.xml XML 163967
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 21988769
SIC: 2834 Pharmaceutical Preparations